BTIG raised the firm’s price target on Intuitive Surgical to $451 from $421 and keeps a Buy rating on the shares as part of a broader research note discussing the takeaways from the Society of Robotic Surgery annual meeting. Even with the growing competition in the field, robotics remains one of the most compelling investment areas of MedTech given the penetration today and the ability to expand beyond the current total addressable market, the analyst tells investors in a research note. BTIG adds that Intuitive Surgical is the clear leader, with the number of systems either commercial or in development having grown into the hundreds globally.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ISRG:
- Intuitive Announces FDA Clearance of Revised da Vinci Xi and X Labeling on Radical Prostatectomy
- Intuitive Surgical announces FDA clearance of revised da Vinci Xi, X labeling
- PayPal upgraded, UiPath downgraded: Wall Street’s top analyst calls
- Intuitive Surgical initiated with a Buy at Goldman Sachs
- Intuitive Surgical management to meet with Piper Sandler